KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) EBT (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of EBT readings, the most recent being $437.0 million for Q1 2026.

  • On a quarterly basis, EBT rose 48.64% to $437.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.4 billion, a 361.19% increase, with the full-year FY2025 number at $1.2 billion, up 195.25% from a year prior.
  • EBT hit $437.0 million in Q1 2026 for Teva Pharmaceutical Industries, up from $80.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $646.0 million in Q3 2025 to a low of -$1.2 billion in Q4 2022.
  • Median EBT over the past 5 years was $64.0 million (2023), compared with a mean of -$145.7 million.
  • Biggest five-year swings in EBT: crashed 774.31% in 2022 and later skyrocketed 299.38% in 2025.
  • Teva Pharmaceutical Industries' EBT stood at -$1.2 billion in 2022, then skyrocketed by 142.78% to $507.0 million in 2023, then tumbled by 148.72% to -$247.0 million in 2024, then skyrocketed by 132.39% to $80.0 million in 2025, then surged by 446.25% to $437.0 million in 2026.
  • The last three reported values for EBT were $437.0 million (Q1 2026), $80.0 million (Q4 2025), and $646.0 million (Q3 2025) per Business Quant data.